Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro

International Journal of Oncology

Volumn 49, Issue 1, 2016, Pages 133-143

  Rogers Broadway, Karly Rai ^a   Chudasama, Dimple ^a   Pados, George ^b   Tsolakidis, Dimitris ^b   Goumenou, Anastasia ^a,c   Hall, Marcia ^a,d   Karteris, Emmanouil ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Ovarian cancer; Rapalogues; Resveratrol; S6K

Indexed keywords

CASPASE 9; DACTOLISIB; DEPTOR PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN SERINE THREONINE KINASE; RAPALOGUE; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RAPTOR PROTEIN; RESVERATROL; RICTOR PROTEIN; S6 KINASE; UNCLASSIFIED DRUG; CARRIER PROTEIN; DEPTOR PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; RICTOR PROTEIN, HUMAN; RPTOR PROTEIN, HUMAN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CELL MIGRATION ASSAY; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MDAH 2774 CELL LINE; OVARIAN CANCER CELL LINE; OVARIAN TISSUE; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SKOV3 CELL LINE; TREATMENT RESPONSE; UPREGULATION; WOUND HEALING ASSAY; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; OVARIAN NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CARCINOMA; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINOLINES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84978427691     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3531     Document Type: Article

References (31)

1. De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E, Mezzanzanica D, Turatti F, et al: Gene expression profiling of advanced ovarian cancer: Characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 23: 8171-8183, 2004.
2. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
3. Kim SH, Juhnn YS and Song YS: Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann NY Acad Sci 1095: 82-89, 2007.
4. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
5. Huang S and Houghton PJ: Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic. Curr Opin Investig Drugs 3: 295-304, 2002.
6. Kurmasheva RT, Huang S and Houghton PJ: Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 95: 955-960, 2006.
7. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC and Testa JR: RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67: 2408-2413, 2007.
8. Squillace RM, Miller D, Cookson M, Wardwell SD, Moran L, Clapham D, Wang F, Clackson T and Rivera VM: Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther 10: 1959-1968, 2011.
9. Takano M, Kikuchi Y, Kudoh K, Goto T, Furuya K, Kikuchi R, Kita T, Fujiwara K, Shiozawa T and Aoki D: Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: A report of six cases. Int J Clin Oncol 16: 605-609, 2011.
10. Foster H, Coley HM, Goumenou A, Pados G, Harvey A and Karteris E: Differential expression of mTOR signalling components in drug resistance in ovarian cancer. Anticancer Res 30: 3529-3534, 2010.
11. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, et al: The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622, 2009.
12. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
13. Jacob F, Guertler R, Naim S, Nixdorf S, Fedier A, Hacker NF and Heinzelmann-Schwarz V: Careful selection of reference genes is required for reliable performance of RT-qPCR in human normal and cancer cell lines. PLoS One 8: e59180, 2013.
14. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, et al; Ovarian Cancer Association Consortium: Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies. Lancet Oncol 13: 385-394, 2012.
15. Brinton LA, Sakoda LC, Sherman ME, Frederiksen K, Kjaer SK, Graubard BI, Olsen JH and Mellemkjaer L: Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev 14: 2929-2935, 2005.
16. Merritt MA, Green AC, Nagle CM and Webb PM; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group: Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122: 170-176, 2008.
17. Fagone P, Donia M, Mangano K, Quattrocchi C, Mammana S, Coco M, Libra M, McCubrey JA and Nicoletti F: Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. Basic Clin Pharmacol Toxicol 112: 63-69, 2013.
18. Treeck O, Wackwitz B, Haus U and Ortmann O: Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 102: 292-299, 2006.
19. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS and Sabatini DM: DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886, 2009.
20. Zitzmann K, Rüden J, Brand S, Göke B, Lichtl J, Spöttl G and Auernhammer CJ: Compensatory activation of Akt in response to mTOR and Raf inhibitors-a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 295: 100-109, 2010.
21. Hisamatsu T, Mabuchi S, Matsumoto Y, Kawano M, Sasano T, Takahashi R, Sawada K, Ito K, Kurachi H, Schilder RJ, et al: Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary. Mol Cancer Ther 12: 1367-1377, 2013.
22. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, et al: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074, 2008.
23. Durbas M, Horwacik I, Boratyn E, Kamycka E and Rokita H: GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines. Int J Oncol 47: 1143-1159, 2015.
24. Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, et al: mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One 8: e62104, 2013.
25. Kondo A, Otsuka T, Kuroyanagi G, Yamamoto N, Matsushima-Nishiwaki R, Mizutani J, Kozawa O and Tokuda H: Resveratrol inhibits BMP-4-stimulated VEGF synthesis in osteoblasts: Suppression of S6 kinase. Int J Mol Med 33: 1013-1018, 2014.
26. Zhang M, Zhou X and Zhou K: Resveratrol inhibits human nasopharyngeal carcinoma cell growth via blocking pAkt/p70S6K signaling pathways. Int J Mol Med 31: 621-627, 2013.
27. Ip CK, Yung S, Chan TM, Tsao SW and Wong AS: p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroidperitoneum interaction and P-cadherin/b1 integrin signaling activation. Oncotarget 5: 9133-9149, 2014.
28. Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, et al: Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. Breast Cancer Res 16: R6, 2014.
29. Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A, Poggi V, Venuta S and Romano MF: Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 106: 1400-1406, 2005.
30. Hahn M, Li W, Yu C, Rahmani M, Dent P and Grant S: Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 4: 457-470, 2005.
31. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA and Thomas G: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120: 747-759, 2005.